Goal Reached Thanks to every supporter — we hit 100%!

Goal: 1000 CNY · Raised: 1000 CNY

100.0%
Buy Us a Coffee

CVE-2022-23056— ERPNext - Stored XSS leads to account takover

EPSS 0.24% · P47
Get alerts for future matching vulnerabilitiesLog in to subscribe

I. Basic Information for CVE-2022-23056

Vulnerability Information
Have questions about the vulnerability? See if Shenlong's analysis helps!
View Shenlong Deep Dive ↗

Although we use advanced large model technology, its output may still contain inaccurate or outdated information.Shenlong tries to ensure data accuracy, but please verify and judge based on the actual situation.

Vulnerability Title
ERPNext - Stored XSS leads to account takover
Source: NVD (National Vulnerability Database)
Vulnerability Description
In ERPNext, versions v13.0.0-beta.13 through v13.30.0 are vulnerable to Stored XSS at the Patient History page which allows a low privilege user to conduct an account takeover attack.
Source: NVD (National Vulnerability Database)
CVSS Information
N/A
Source: NVD (National Vulnerability Database)
Vulnerability Type
在Web页面生成时对输入的转义处理不恰当(跨站脚本)
Source: NVD (National Vulnerability Database)
Vulnerability Title
ERPNext 跨站脚本漏洞
Source: CNNVD (China National Vulnerability Database)
Vulnerability Description
ERPNext是印度ERPNext公司的一套开源的企业资源计划解决方案。 ERPNext v13.0.0-beta.13 到 v13.30.0版本存在跨站脚本漏洞，攻击者利用该漏洞可以用低权限用户进行帐户接管攻击。
Source: CNNVD (China National Vulnerability Database)
CVSS Information
N/A
Source: CNNVD (China National Vulnerability Database)
Vulnerability Type
N/A
Source: CNNVD (China National Vulnerability Database)

Affected Products

VendorProductAffected VersionsCPESubscribe
erpnexterpnext v13.0.0-beta.13 ~ unspecified -

II. Public POCs for CVE-2022-23056

#POC DescriptionSource LinkShenlong Link
AI-Generated POCPremium

No public POC found.

Login to generate AI POC

III. Intelligence Information for CVE-2022-23056

请登录查看更多情报信息。

IV. Related Vulnerabilities

Same product: erpnext
Same vendor: erpnext
Same weakness: CWE-79

V. Comments for CVE-2022-23056

No comments yet

Leave a comment